Syngene International plans to add bioconjugation suite for end-to-end Antibody-Drug conjugates development

With this new capability, Syngene will offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing.

The OEB-5 rated suite will accelerate ADC development timelines by enabling both Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single site, complementing Syngene’s existing commercial capabilities in payload and linker manufacturing. Expected to be operational within this financial year, the conjugation facility will also support a range of advanced conjugates and related modalities. These services are further strengthened by collocated analytical and bioanalytical capabilities, ensuring seamless integration across the development lifecycle.

“The discovery and development of ADCs is complex, often involving multiple vendors and geographically dispersed sites, which adds substantial supply chain complexity and potential delays,” said Alex Del Priore, Head - LM CDMO, Syngene International. “By integrating bioconjugation capabilities with our commercial-scale biologics, payload, and linker production units in Bengaluru, we can significantly compress development timelines and offer a unique, end-to-end pathway from early discovery through to GMP manufacturing.” he added.

Syngene is scaling its capabilities to support clinical programs and plans to develop commercial-scale capabilities in the future.

Additionally, the laboratories will offer process development, analytical characterization, and scale-up for both early- and late-stage programs. This addition will further enhance Syngene’s ability to serve biotech and biopharma clients seeking agile, science-driven partners for their ADC programs.

Syngene will be present at CPHI Frankfurt, Ground Level, Hall Number 6, Booth Number C66.

Read also: Syngene International names Chethan Yogesh as Company Secretary, Compliance Officer